Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of July 11, 2026, BCAX trades at $28.90 with a market cap of $1.95B and a P/E ratio of -11.39. BCAX moved -2.73% today. Year to date, BCAX is +71.78%; over the trailing twelve months it is +191.43%. Its 52-week range spans $7.80 to $30.99. Analyst consensus is strong buy with an average price target of $32.11. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Bicara Therapeutics Inc. Common Stock (BCAX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. BCAX moved -2.73% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $28.90 |
| Market Cap | $1.95B |
| P/E Ratio | -11.39 |
| EPS | $-2.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $30.99 |
| 52-Week Low | $7.80 |
| Volume | 490.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-137.95M |
| Gross Margin | 0.00% |
11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.11.